Emergent Biosolutions Inc (EBS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $297.69M
Last updated: Nov 17, 2026 at 11:05 AM ET
Emergent Biosolutions Inc (EBS) Financials: Revenue, Profit and Cash Flow
Emergent Biosolutions reported revenue of $742.90M for the fiscal year ended Dec 31, 2025, down 28.8% from the year before. That year, net income was $52.60M with a net margin of 7.1%, operating cash flow was $170.60M and free cash flow was $156.80M. The quarter ended Sep 30, 2026 had revenue of $110.00M and net income of -$32.70M.
Revenue and Margins
The operating margin was 13.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $488.80M, a compound annual rate of 4.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $742.90M | -28.8% | 56.1% | 13.5% | 7.1% |
| Dec 2024 | $1.04B | -0.5% | 34.7% | -10.4% | -18.3% |
| Dec 2023 | $1.05B | +21314.3% | 32.8% | -69.2% | -72.5% |
| Dec 2022 | $4.90M | -99.9% | 100.0% | -3469.4% | -4318.4% |
| Dec 2021 | $4.57B | +189.8% | 67.3% | 7.5% | 4.8% |
| Dec 2020 | $1.58B | +42.6% | 66.0% | 27.8% | 19.4% |
| Dec 2019 | $1.11B | +41.4% | 60.8% | 10.3% | 4.9% |
| Dec 2018 | $782.40M | +39.5% | 58.8% | 11.5% | 8.0% |
| Dec 2017 | $560.90M | +14.8% | 66.5% | 22.2% | 14.7% |
| Dec 2016 | $488.80M | N/A | 74.2% | 21.6% | 10.6% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $742.90M | $1.04B | $1.05B | $4.90M | $4.57B | $1.58B | $1.11B | $782.40M | $560.90M | $488.80M |
| Cost of revenue | $326.20M | $681.30M | $705.40M | $0 | $1.50B | $537.00M | $433.50M | $322.30M | $187.70M | $126.30M |
| Gross profit | $416.70M | $362.30M | $343.90M | $4.90M | $3.07B | $1.04B | $672.50M | $460.10M | $373.20M | $362.50M |
| Research and development | $53.20M | $70.70M | $111.40M | $188.30M | $235.20M | $237.90M | $226.20M | $142.80M | $97.40M | $106.90M |
| Operating income | $100.10M | -$108.70M | -$726.40M | -$170.00M | $341.40M | $438.50M | $114.10M | $89.80M | $124.30M | $105.50M |
| Net income | $52.60M | -$190.60M | -$760.50M | -$211.60M | $219.50M | $305.80M | $54.50M | $62.70M | $82.60M | $51.80M |
| EBITDA | $259.90M | $43.70M | -$499.40M | -$34.30M | $427.40M | $561.20M | $229.50M | $154.50M | $169.50M | $145.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $110.00M | $234.30M | $156.10M | $148.70M | $231.10M | $140.90M | $222.20M | $194.70M | $293.80M | $254.70M | $300.40M | -$755.70M |
| Gross profit | $29.20M | $137.20M | $84.10M | $63.80M | $145.20M | $74.00M | $133.70M | $76.70M | $171.20M | -$41.40M | $155.80M | -$573.40M |
| Operating income | -$37.30M | -$125.10M | $10.50M | -$27.90M | $76.50M | $1.60M | $49.90M | -$9.50M | $64.50M | -$203.50M | $39.80M | -$43.80M |
| Net income | -$32.70M | -$180.20M | $6.80M | -$54.60M | $51.20M | -$12.00M | $68.00M | -$31.30M | $114.80M | -$283.10M | $9.00M | -$49.50M |
Balance Sheet
As of Dec 2025, total debt of $572.10M exceeded cash and equivalents by $366.70M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B | $2.88B | $2.33B | $2.23B | $1.07B | $970.11M |
| Current assets | $662.50M | $598.70M | $679.50M | $1.21B | $1.27B | $1.20B | $686.20M | $620.80M | $485.40M | $510.22M |
| Cash and equivalents | $205.40M | $99.50M | $111.70M | $642.60M | $576.10M | $621.30M | $167.80M | $112.20M | $178.30M | $271.51M |
| Total liabilities | $796.00M | $906.90M | $1.17B | $1.78B | $1.35B | $1.44B | $1.24B | $1.22B | $157.90M | $373.91M |
| Short-term debt | $0 | $2.70M | $413.70M | $957.30M | $31.60M | $33.80M | $12.90M | $10.10M | $0 | $20.00M |
| Long-term debt | $572.10M | $663.70M | $446.50M | $448.50M | $809.40M | $841.00M | $798.40M | $784.50M | $13.50M | $248.09M |
| Shareholder equity | $522.60M | $482.80M | $649.30M | $1.39B | $1.61B | $1.45B | $1.09B | $1.01B | $912.30M | $596.21M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $995.20M | $1.12B | $1.32B | $1.32B | $1.46B | $1.42B | $1.43B | $1.40B | $1.48B | $1.51B | $1.80B | $1.83B |
| Total liabilities | $682.00M | $775.40M | $797.30M | $796.00M | $878.50M | $880.90M | $873.40M | $914.10M | $969.40M | $1.13B | $1.14B | $1.19B |
| Cash and equivalents | $175.70M | $139.70M | $160.30M | $205.40M | $245.50M | $267.30M | $149.10M | $105.60M | $149.90M | $69.70M | $78.50M | $111.70M |
| Shareholder equity | $313.20M | $341.40M | $523.10M | $522.60M | $582.50M | $536.20M | $552.70M | $482.80M | $508.40M | $386.30M | $663.90M | $649.30M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 91.9% of operating cash flow. Share repurchases came to 15.9% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $170.60M | $58.70M | -$206.30M | -$34.10M | $320.20M | $536.90M | $188.00M | $41.80M | $208.10M | $54.60M |
| Capital expenditures | $13.80M | $22.90M | $51.60M | $359.50M | $224.10M | $141.90M | $86.90M | $72.10M | $132.40M | $76.20M |
| Free cash flow | $156.80M | $35.80M | -$257.90M | -$393.60M | $96.10M | $395.00M | $101.10M | -$30.30M | $75.70M | -$21.60M |
| Dividends paid | N/A | N/A | $5.00M | N/A | $15.90M | $17.80M | $800.00K | N/A | $0 | $0 |
| Share repurchases | $24.90M | $0 | $0 | $82.10M | $106.00M | $0 | $0 | $100.00K | $33.10M | $0 |
| Investing cash flow | $69.40M | $125.20M | $212.30M | -$381.30M | -$224.10M | -$151.90M | -$96.90M | -$897.20M | -$249.90M | -$76.20M |
| Financing cash flow | -$136.60M | -$190.00M | -$535.70M | $481.20M | -$141.00M | $69.50M | -$35.90M | $788.70M | -$51.40M | -$19.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $100.10M | $56.10M | -$33.80M | $77.70M | -$2.30M | $106.40M | -$11.20M | -$79.90M | $153.70M | $47.50M | -$62.60M | $32.10M |
| Capital expenditures | $3.30M | $2.10M | $2.40M | $3.90M | $3.40M | $2.90M | $3.60M | $1.70M | $5.80M | $4.60M | $10.80M | $11.40M |
| Free cash flow | $96.80M | $54.00M | -$36.20M | $73.80M | -$5.70M | $103.50M | -$14.80M | -$81.60M | $147.90M | $42.90M | -$73.40M | $20.70M |
Frequently Asked Questions About EBS
What is Emergent Biosolutions' annual revenue?
Emergent Biosolutions reported revenue of $742.90M for the fiscal year ended Dec 31, 2025.
How fast is Emergent Biosolutions' revenue growing?
Revenue was down 28.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 433.2%.
Is Emergent Biosolutions profitable?
Yes. Emergent Biosolutions reported net income of $52.60M for the fiscal year ended Dec 31, 2025, with a net margin of 7.1%.
How much free cash flow does EBS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $170.60M minus capital expenditures of $13.80M produced free cash flow of $156.80M.
How much debt does Emergent Biosolutions have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $572.10M, short-term debt of $0 and cash and equivalents of $205.40M.
EBS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts